MIRA INFORM REPORT

 

 

Report Date :

13.09.2014              

 

IDENTIFICATION DETAILS

 

Name :

CHEMILLENNIUM INTERNATIONAL (H.K.) LTD.

 

 

Registered Office :

Room 1908, 19/F., Solo, 83 Bedford Road, Taikoktsui, Kowloon

 

 

Country :

Hong Kong

 

 

Date of Incorporation :

06.12.1999

 

 

Com. Reg. No.:

30554053

 

 

Legal Form :

private limited liability company

 

 

Line of Business :

Importer and Re-exporter of all kinds of chemicals, chemical raw materials, pharmaceuticals

 

 

No. of Employees :

7

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No complaints

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – June 01, 2014

 

Country Name

Previous Rating

(31.03.2014)

Current Rating

(01.06.2014)

Hong Kong

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low Risk

 

A2

Moderate Low Risk

 

B1

Moderate Risk

 

B2

Moderate High Risk

 

C1

High Risk

 

C2

Very High Risk

 

D

 


 

HONG KONG - ECONOMIC OVERVIEW

 

Hong Kong has a free market economy, highly dependent on international trade and finance - the value of goods and services trade, including the sizable share of re-exports, is about four times GDP. Hong Kong has no tariffs on imported goods, and it levies excise duties on only four commodities, whether imported or produced locally: hard alcohol, tobacco, hydrocarbon oil, and methyl alcohol. There are no quotas or dumping laws. Hong Kong's open economy left it exposed to the global economic slowdown that began in 2008. Although increasing integration with China, through trade, tourism, and financial links, helped it to make an initial recovery more quickly than many observers anticipated, its continued reliance on foreign trade and investment leaves it vulnerable to renewed global financial market volatility or a slowdown in the global economy. The Hong Kong government is promoting the Special Administrative Region (SAR) as the site for Chinese renminbi (RMB) internationalization. Hong Kong residents are allowed to establish RMB-denominated savings accounts; RMB-denominated corporate and Chinese government bonds have been issued in Hong Kong; and RMB trade settlement is allowed. The territory far exceeded the RMB conversion quota set by Beijing for trade settlements in 2010 due to the growth of earnings from exports to the mainland. RMB deposits grew to roughly 12% of total system deposits in Hong Kong by the end of 2013. The government is pursuing efforts to introduce additional use of RMB in Hong Kong financial markets and is seeking to expand the RMB quota. The mainland has long been Hong Kong's largest trading partner, accounting for about half of Hong Kong's total trade by value. Hong Kong's natural resources are limited, and food and raw materials must be imported. As a result of China's easing of travel restrictions, the number of mainland tourists to the territory has surged from 4.5 million in 2001 to 34.9 million in 2012, outnumbering visitors from all other countries combined. Hong Kong has also established itself as the premier stock market for Chinese firms seeking to list abroad. In 2012 mainland Chinese companies constituted about 46.6% of the firms listed on the Hong Kong Stock Exchange and accounted for about 57.4% of the Exchange's market capitalization. During the past decade, as Hong Kong's manufacturing industry moved to the mainland, its service industry has grown rapidly. Credit expansion and tight housing supply conditions have caused Hong Kong property prices to rise rapidly; consumer prices increased by more than 4% in 2013. Lower and middle income segments of the population are increasingly unable to afford adequate housing. Hong Kong continues to link its currency closely to the US dollar, maintaining an arrangement established in 1983. In 2013, Hong Kong and China signed new agreements under the Closer Economic Partnership Agreement, adopted in 2003 to forge closer ties between Hong Kong and the mainland. The new measures, effective from January 2014, cover services and trade facilitation, and will improve access to the mainland's service sector for Hong Kong-based companies

Source : CIA

 


Company name           

 

CHEMILLENNIUM  INTERNATIONAL  (H.K.)  LTD.

 

 

Company ADDRESS

 

Room 1908, 19/F., Solo, 83 Bedford Road, Taikoktsui, Kowloon, Hong Kong.

 

PHONE:                  852-2191 9580

 

FAX:                       852-2191 9518

 

E-MAIL:                  chemille@netvigator.com

chemillennium@mail.com

 

 

MANAGEMENT

 

Managing Director:  Mr. Purushotamdas Asumal Panjabi

 

 

SUMMARY

 

Incorporated on:             6th December, 1999.

 

Organization:                 Private Limited Company.

 

Capital: Nominal:           HK$6,000,000.00

Issued:                          HK$6,000,000.00

 

Business Category:        Pharmaceutical Trader.

 

Employees:                   7.

 

Main Dealing Banker:     The Bank of East Asia Ltd., Hong Kong.

 

Banking Relation:           Satisfactory.


Company name 

 

CHEMILLENNIUM  INTERNATIONAL  (H.K.)  LTD.

 

 

Company ADDRESS

 

Registered Head Office:-

Room 1908, 19/F., Solo, 83 Bedford Road, Taikoktsui, Kowloon, Hong Kong.

 

Associated Companies:-

Chemill Inc., USA.

Chemillennium International Ltd., China.

Shenzhen Chemillennium Import & Export Co. Ltd., China.

 

 

BUSINESS REGISTRATION NUMBER

 

30554053

 

 

COMPANY FILE NUMBER

 

0696828

 

 

MANAGEMENT

 

Managing Director:  Mr. Purushotamdas Asumal Panjabi

Contact Person:       Ms. Kylie Ng

 

 

CAPITAL

 

Nominal Share Capital: HK$6,000,000.00 (Divided into 6,000,000 shares of HK$1.00 each)

 

Issued Share Capital: HK$6,000,000.00


SHAREHOLDERS

 

(As per registry dated 06-12-2013)

Name

 

No. of shares

Purushotamdas Asumal PANJABI

 

1,800,000

Neetu Pratap TEJSINGHANI

 

600,000

Raj Pratap TEJSINGHANI

 

1,800,000

Deepak Pratap TEJSINGHANI

 

1,800,000

 

 

––––––––

 

Total:

6,000,000

=======

 

DIRECTORS  

(As per registry dated 06-12-2013)

Name

(Nationality)

 

Address

Purushotamdas Asumal PANJABI

Flat D, 31/F., Tower 3, The Waterfront, 1 Austin Road West, Kowloon, Hong Kong.

 

Deepak Pratap TEJSINGHANI

Flat D, 31/F., Tower 3, The Waterfront, 1 Austin Road West, Kowloon, Hong Kong.

 

 

SECRETARY

(As per registry dated 28-04-2014)

Name

Address

Co. No.

Co-Convenience Consultants Ltd.

Unit 1801, 18/F., Bonham Trade Centre, 50 Bonham Strand, Sheung Wan, Hong Kong.

0464271

 

 

HISTORY

 

The subject was incorporated on 6th December, 1999 as a private limited liability company under the Hong Kong Companies Ordinance.

Formerly the subject’s registered office was located at Room 17A, 17/F., Man Hing Commercial Building, 79-83 Queen’s Road Central, Hong Kong where was the operating office of an accountant firm Co-Convenience Consultants Ltd.  As the accountant firm moved to Room 2001, 20/F., Nan Fung Tower, 173 Des Voeux Road Central, Hong Kong in December 2006, and further to Room 1101-1104, 11/F. of the same building with effect from 1st August, 2010, so did the subject.

Formerly the subject’s head office was located at Room B, 8/F., R & T Centre, 81-83 Larch Street, Mongkok, Kowloon, Hong Kong, moved to Suite 1402, 14/F., World Commerce Centre, 11 Canton Road, Tsimshatsui, Kowloon, Hong Kong in 2010, to Room B, 8/F., R & T Centre, 81-83 Larch Street, Mongkok, Kowloon, Hong Kong in February 2012, and further moved to the present address in mid 2013.

Apart from these, neither material change nor amendment has been ever traced and noted.

 

 

OPERATIONS

 

Activities:                      Importer and Re-exporter.

 

Lines:                           All kinds of chemicals, chemical raw materials, pharmaceuticals.

 

Employees:                   7.

 

Commodities Imported:   Imported from China, Africa, Europe, India, etc.

 

Markets:                       Worldwide countries.

 

Terms/Sales:                 L/C, T/T, etc.

 

Terms/Buying:               L/C, T/T, D/A, D/P, etc.

 

 

FINANCIAL INFORMATION

 

Nominal Share Capital:   HK$6,000,000.00 (Divided into 6,000,000 shares of HK$1.00 each)

 

Issued Share Capital:     HK$6,000,000.00

 

Alternation of Capital:-

Initially

paid up

HK$      10,000.00

26-06-2007

paid up

HK$      5,990,000.00

 

 

–––––––––––––––

Total:

paid up

HK$      6,000,000.00

==============

 

Increase of Nominal Capital:-

From

HK$10,000.00

to

HK$6,000,000.00

on

26-06-2007

 

Mortgage or Charge:       (See attachment)

 

Profit or Loss:                Making a small profit every year.

 

Condition:                      Keeping in an active condition.

 

Facilities:                      Making active use of general banking facilities.

 

Payment:                      Met trade commitments as contracted.

 

Commercial Morality:     Satisfactory.

 

Bankers:-

The Bank of East Asia Ltd., Hong Kong.

Citibank N.A., Hong Kong Branch.

The Hongkong & Shanghai Banking Corp. Ltd., Hong Kong.

 

Standing:                      Good.

 

 

GENERAL

 

Having issued 6 million ordinary shares of HK$1.00 each, Chemillennium International (H.K.) Ltd. is a private limited company jointly owned by Mr. Purushotamdas Asumal Panjabi, holding 30% interests; Mr. Neetu Pratap Tejsinghani, holding 10%; Raj Pratap Tejsinghani, 30%; and Deepak Pratap Tejsinghani, also 30%.  In June 2007, the subject increased its issued share capital from HK$10,000.00 to HK$6 million.  P A Panjabi and D P Tejsinghani are directors of the subject.  The subject is owned by an Indian family.

The subject’s business is chiefly handled by Panjabi.  He is a Hong Kong ID Card holder and has got the right to reside in Hong Kong permanently.

The subject is an international pharmaceutical company specialised in supplying its global customers with chemical and natural raw materials and pharmaceuticals.  It in fact is a member of the Chemillennium Group which is a family-owned company.  The family has been involved in the healthcare industry for over three decades.  Now, the Group offers its worldwide customers with a broad range of products that include neutraceuticals, both natural and synthetic, sweeteners, natural extracts and botanicals.  Its customers are in over 80 countries of the world.  Currently, the Group has set up a number of affiliated or associated companies in Asia and the United States.

As a member of the Group and an associated company of the subject, Chemillennium International Ltd. [CIL] is in Shenzhen Special Economic Zone, China.

CIL is trading in the following pharmaceuticals: 10-deacetylbaccatin III, colchicine, digoxin, hyoscine hydrobromide, nicergoline, reserpine, vincamine, vinpocetine, yohimbine HCL, cinchona ledgeriana bark, griffonia simplicifolia seeds, pausinstalia yohimbe barks, prunus africana, etc.

Another significant firm in China is known as Shenzhen Chemillennium Import & Export Co. Ltd. [Shenzhen Chemillennium].  This firm is also a pharmaceutical trader.  Trading in chemical raw materials and pharmaceutical intermediates, Shenzhen Chemillennium is the agent in China of a number of significant pharmaceutical manufacturers from Germany, Spain, Austria, the Netherlands, France, Mexico, South Korea, India, Taiwan, South Africa, etc.  Business is rather active.

According to the subject, Shenzhen Chemillennium is trading in the following pharmaceuticals:-

·         5-htp5-99%;

·         Colchicine;

·         Digoxin;

·         Domperidone;

·         Hyoscine Hydrobromide;

·         Hyoscine N Butyl Bromide;

·         Omeprazole Pellet 8.5%;

·         Reserpine;

·         vinpocetine; &

·         Yohimbine Hcl 99%.

Shenzhen Chemillennium is located at Room 607, North Block, International Business Building, Jiabin Road, Luohu District, Shenzhen SEZ, China.

The subject’s pharmaceuticals and raw materials are sourced from China, imported from South Africa, Europe, India, etc.  Products are re-exported to worldwide countries.  Prime markets are India, the other Asian countries.  Business has been rather active.

The subject is carrying the following significant products: Andrographolide, Ajmaline, Boldine, Camptohecin 98%, Colchicine USP, Curcumin, Colchicoside, 10-Deacetylbaccatin III, 18ß Glycyrrhetinic Acid, Emetine HCL BP/USP, Esculoside, Escin, Forskolin, Glibenclamide, Glipizide, Hyoscine N Butyl, Bromide BP, Hyoscine Hydrobromide BP/USP, Lycopene, Methoxsalen USP, Monoammounium, Glycyrrhizinate, Nicergoline, Oleanolic Acid, Paclitaxel, Podophyllum BP, Podophyllotoxin, Reserpine BP/USP, Thiocolchicoside, etc.

Business chiefly administered by Panjabi, the subject has developed long term business ties with a number of foreign suppliers and overseas customers.  Annual sales turnover is rather significant.  Business has been expanding as more staff have been recruited since December 2013.  The contact person of the subject Ms. Kylie Ng is a Hongkongnese.

The history of the subject in Hong Kong is over fourteen years and nine months.  Business is active.

The subject owns premises in Hong Kong.

On the whole, consider it good for normal business engagements.

REMARK

 

Property information of the company:-

Property Location:                  

Flat D on 31/F. of Tower III, The Waterfront, 1 Austin Road West, Kowloon, Hong Kong.

Owner:  Chemillennium International (H.K.) Ltd.

Date of Purchase:  n.a.

Purchased Price:  n.a.

Incumbrances:-

Date of Mortgage

Amount Consideration

Mortgagee

Nature

21-12-2004

-

The Bank of East Asia Ltd., Hong Kong.

Legal charge to secure general banking facilities

 


MORTGAGE OR CHARGE

 

Date

Particulars

Amount

21-12-2004

Instrument:      Legal Charge

Property:

1,105/25,901,816th parts or shares of and in Kowloon Inland Lot No. 11080 (Flat D on 31/F. of Tower III of The Waterfront, 1 Austin Road West, Kowloon, Hong Kong.)

Mortgagee:      The Bank of East Asia Ltd., Hong Kong.

To secure general banking facilities

16-07-2007

Instrument:      Charge Over Receivables and Insurance

Property:

1)   First fixed charge of (i) all the Chargor’s right, benefit, and interest in the Agreement and the Insurance Contract; (ii) all the Chargor’s right, benefit, title and interest in and to all receivable and accounts receivables, notes, bills, invoices, acceptances, or other form of obligations or debts; and (iii) all right, benefit, title and interest of the Chargee to the insurance proceeds under the Insurance Contract and all the credit balance

2)   By way of first floating charge, the property, assets, and rights

Mortgagee:      Citibank N.A., Hong Kong Branch.

All moneys, obligations and liabilities

22-07-2010

Instrument:      Deposit Deed

Property:

By way of a first fixed charge and as a continuing security for the Obligations, the Company charges and assigns absolutely all its rights, title to and interest in the Accounts and all Deposits

Mortgagee:      Citibank N.A., Hong Kong Branch.

All moneys


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.60.84

UK Pound

1

Rs.98.72

Euro

1

Rs.78.64

 

INFORMATION DETAILS

 

Analysis Done by :

KAR

 

 

Report Prepared by :

PDT

 

               

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.